Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
October 2020
-
Key Release
Novartis au T3: performance solide, croissance de 11% du résultat opérationnel core, chiffre d’affaires net proche de l’an dernier, pipeline en fort progrès; hausse du résultat opérationnel core prévu
Chiffre d’affaires net des activités poursuivies1 au T3 en ligne avec celui de l’exercice précédent (tcc2, +1% USD): Les moteurs de la croissance ont été notamment Entresto USD 632 millions… -
Key Release
Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.
Q3 net sales from continuing operations1 were in line with prior year (cc2, +1% USD): Growth drivers included Entresto USD 632 million (+45% cc), Zolgensma USD 291 million (+79% cc), Cosentyx USD… -
Key Release
Novartis im 3. Qu. mit solider Performance: operatives Kernergebnis steigt um 11%, Nettoumsatz auf Vorjahresniveau, starke Pipeline-Fortschritte; Jahresprognose für operatives Kernergebnis angehoben
Im dritten Quartal 2020 lag der Nettoumsatz der fortzuführenden Geschäftsbereiche1 auf dem Niveau des Vorjahres (kWk2, +1% USD): Zu den Wachstumsträgern gehörten Entresto (USD 632 … -
Media Release
Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)
C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1–3 Iptacopan (LNP023) is a potential first-in-class, oral,… -
In The News
Overcoming manufacturing challenges
Novartis Technical Operations adapts to meet drug donation plans and ensure business continuity. -
Media Release
Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)
Orphan drug designation is reserved for medicines treating rare, life-threatening or chronically debilitating diseases IgA nephropathy (IgAN), while rare, is the most common form of… -
Media Release
Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)
Huntington’s disease is a rare, inherited neurodegenerative disease that leads to progressive disability and deathThere are no approved disease modifying therapies that delay disease onset or slow… -
Key Release
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1Cardiovascular disease (CVD) claims 3.9… -
Media Release
Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)
The European Medicines Agency has granted iptacopan a priority medicines (PRIME) designation in C3 glomerulopathy (C3G). PRIME is granted for medicines that may offer major therapeutic advance… -
Featured News
World Sight Day 2020
Learn how we’re working with partners like the International Agency for the Prevention of Blindness to eliminate preventable blindness.
-
Story Access to Healthcare
Meet a visionary who beat the odds to realize his vision of inclusive eye care
Dr. Theophile Tuyisabe is one of only 18 ophthalmologists in Rwanda. We spoke with him about how he does it.
-
Media Release
New Phase III analysis demonstrates Novartis Beovu® showed improvement in best-corrected visual acuity in wet AMD patients with early persistent fluid
In a post-hoc analysis of HAWK and HARRIER, fewer Beovu (brolucizumab) patients had early persistent fluid (12.5% vs. 20.4% of aflibercept patients), defined as the presence of intra-retinal fluid…